Investigational drug · Phase 3
Psilocybin
Also called: COMP360
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
297
Any phase or sponsor naming "Psilocybin"
First trial start
2022
Oct 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Psilocybin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Treatment Resistant Depression
- Major Depressive Disorder
- Anorexia Nervosa
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Psilocybin" as an intervention, largest first.
- Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDPivotal-lookingActive, not recruiting
COMPASS PathwaysIndustry
NCT05711940 · 572 participants · Start Feb 14, 2023 · Primary completion Nov 13, 2025
Drug: Psilocybin · For: Treatment Resistant Depression
Sites: Gilbert, Arizona; Bellflower, California; Encino, California · 116 sites in all
- Psilocybin for Opioid Use Disorder (OUD)Pivotal-lookingRecruiting
NYU Langone HealthAcademic, hospital or other
NCT06796062 · 480 participants (planned) · Start Dec 17, 2025 · Primary completion Feb 2029
Drug: Psilocybin · For: Opioid Use Disorder
Sites: Albuquerque, New Mexico; Brooklyn, New York; New York, New York · 5 sites in all
- Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)Pivotal-lookingEnrolling by invitation
Cybin IRL LimitedIndustry
NCT06605105 · 468 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 6, 2028
Drug: CYB003 · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Glendale, California; La Jolla, California · 49 sites in all
- Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentActive, not recruiting
University Hospital, GenevaAcademic, hospital or other
NCT07164287 · 376 participants (planned) · Start Jun 1, 2020 · Primary completion Apr 30, 2025
Drug: Lysergic Acid Diethylamide (LSD) or psilocybin · For: Major Depressive Disorder (MDD); Anxiety Disorders; Substance Use Disorder (SUD) and 1 more
Sites: Geneva, Switzerland
- A Study of Psilocybin for Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Usona InstituteAcademic, hospital or other
NCT03866174 · 347 participants · Start Jan 23, 2020 · Primary completion Jun 28, 2022
Drug: Psilocybin; Niacin · For: Depressive Disorder, Major
Sites: San Francisco, California; Santa Monica, California; New Haven, Connecticut · 11 sites in all
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPivotal-lookingRecruiting
Cybin IRL LimitedIndustry
NCT06793397 · 330 participants (planned) · Start Dec 10, 2025 · Primary completion Jun 7, 2027
Drug: CYB003 · For: Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder and 3 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 79 sites in all
- Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPivotal-lookingRecruiting
COMPASS PathwaysIndustry
NCT07570654 · 300 participants (planned) · Start Sep 14, 2026 · Primary completion Nov 2028
Drug: COMP360 psilocybin · For: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms and 1 more
Sites: Tucson, Arizona; Irvine, California; Los Angeles, California · 20 sites in all
- Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDPivotal-lookingCompleted
COMPASS PathwaysIndustry
NCT05624268 · 258 participants · Start Jan 24, 2023 · Primary completion May 28, 2025
Drug: Psilocybin · For: Treatment Resistant Depression
Sites: Tuscon, Arizona; Culver City, California; Garden Grove, California · 40 sites in all
- Psilocybin Intervention for Veterans Overcoming Treatment-Resistant DepressionPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT07226232 · 240 participants (planned) · Start Aug 3, 2026 · Primary completion Dec 2, 2030
Drug: Psilocybin; Psilocybin · For: Major Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Portland, Oregon · 5 sites in all
- Psilocybin for Major Depressive Disorder (MDD)Pivotal-lookingActive, not recruiting
Usona InstituteAcademic, hospital or other
NCT06308653 · 238 participants · Start Mar 13, 2024 · Primary completion Jan 5, 2026
Drug: Psilocybin 25 mg; Inactive Placebo and 1 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Little Rock, Arkansas · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial.
Novick AM, Love TM, Johnson RL, et al. · J Affect Disord 2027
- Determination of Tryptamines in Biological Specimens.
Varì MR, Aquilina V, Di Trana A, et al. · Methods Mol Biol 2027
- Nursing education for emerging psychedelic-assisted therapy: A role-calibrated curriculum approach.
Yldz E · Nurse Educ Today 2027
- A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy.
Khan FA, Pandupuspitasari NS, Tencomnao T, et al. · J Affect Disord 2026
- Psilocybin enhances conditioned place preference learning in planarians.
Ellenbroek BA, Naylor B, Youn J · Behav Pharmacol 2026
- Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward.
Mallevays M, Berkovitch L · Eur Neuropsychopharmacol 2026
Also in development for Treatment Resistant Depression
- PBOPhase 32 trials
SK Life Science, Inc. · Primary Generalized Epilepsy, Treatment Resistant Depression
- NRX-101Phase 31 trial
NeuroRx, Inc. · Treatment Resistant Depression, Treatment Resistant Depression (TRD)
- BPL-003Phase 22 trials
Beckley Psytech Limited · Treatment Resistant Depression
- NV-5138SPN820Phase 21 trial
Navitor Pharmaceuticals, Inc. · Treatment Resistant Depression
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.